Comparative Pharmacology
Head-to-head clinical analysis: ACCURETIC versus ORETICYL 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCURETIC versus ORETICYL 25.
ACCURETIC vs ORETICYL 25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACCURETIC is a combination of quinapril, an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic. Quinapril inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing diuresis and lowering blood pressure.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive NaCl cotransporter, increasing excretion of sodium, chloride, and water. Deserpidine depletes catecholamines from peripheral sympathetic nerve endings by binding to the vesicular monoamine transporter, reducing vascular resistance and heart rate.
One tablet orally once daily. Initial dose is 20 mg quinapril/12.5 mg hydrochlorothiazide, titrated to maximum 20 mg quinapril/25 mg hydrochlorothiazide.
Hydrochlorothiazide 25 mg orally once daily; may increase to 50 mg daily if needed.
None Documented
None Documented
Quinapril: 0.8 hours; Quinaprilat (active): 2 hours in young healthy adults, prolonged to 3-4 hours in elderly or renal impairment.
2.5 hours; in renal impairment may extend to 8–15 hours.
Renal: approximately 90% (60% unchanged, 30% as metabolites). Fecal/biliary: <10%.
Primarily renal (95% unchanged); minimal biliary (<5%).
Category C
Category C
ACE Inhibitor/Diuretic Combination
Diuretic Combination